Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is used in the management of venous thromboembolic disorders.

• Deep vein thrombosis (prevention): Reduces the risk of clot formation in patients undergoing surgery or immobilisation.
• Deep vein thrombosis (treatment): Promotes resolution of existing thrombi and prevents propagation.
• Pulmonary embolism (prevention): Lowers the incidence of embolic events in high‑risk individuals.
• Pulmonary embolism (treatment): Assists in clot dissolution and prevents recurrence.
• Hemodialysis anticoagulation: Provides safe anticoagulation during extracorporeal dialysis procedures.

• Enoxaparin Sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). This selective blockade reduces thrombin generation and fibrin formation, thereby interrupting the coagulation cascade and preventing clot extension without markedly affecting platelet function.

Enoxaparin Sodium may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Injection‑site bruising or pain: Localised discoloration or discomfort at the subcutaneous injection site.
• Minor bleeding: Epistaxis, gum bleeding or easy bruising.
• Nausea or vomiting: Gastro‑intestinal upset occurring in a minority of patients.
• Elevated liver enzymes: Transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Major bleeding: Life‑threatening haemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT): Immune‑mediated platelet decline with paradoxical thrombosis.
• Allergic reactions: Rash, urticaria or anaphylaxis.
• Spinal/epidural hematoma: Bleeding in the spinal canal following neuraxial procedures.

When prescribing Ledraxen, clinicians should observe several safety considerations to minimise risk.

• Renal function assessment: Adjust dosing in patients with severe renal impairment.
• Platelet monitoring: Check platelet counts regularly to detect HIT early.
• Concomitant anticoagulants: Avoid or closely monitor use with other anticoagulant or antiplatelet agents.
• Active bleeding: Do not initiate therapy in patients with uncontrolled haemorrhage.
• Dose adjustment in extremes of body weight: Consider weight‑based dosing for obesity or low body weight.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid)

• Warfarin or other oral anticoagulants: Combined use markedly increases bleeding risk.
• Direct thrombin inhibitors (e.g., dabigatran): Additive anticoagulation may lead to severe haemorrhage.
• Neuraxial anesthesia or spinal puncture: Heightened risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely)

• NSAIDs or aspirin: May potentiate mucosal bleeding.
• Antiplatelet agents (clopidogrel, ticagrelor): Increase overall bleeding tendency.
• Selective serotonin reuptake inhibitors (SSRIs): Can impair platelet aggregation and raise bleeding risk.